Oncotargets and Therapy Dovepress
暂无分享,去创建一个
Jianguo Zhang | Zhentao Yu | J. Yue | Yuandong Yu | Jinhua Lei | Yanli Li | Guo-xing Wan | Xiongjie Yu | Fengjun Cao | Peng Ren Chuangui Chen
[1] Sehrish Naz,et al. Prognostic Value of Histopathology and Trends in Cervical Cancer , 2022, Pakistan Journal of Medical & Health Sciences.
[2] Hui Zhang,et al. High Expression of GRP78 Promotes Invasion and Metastases in Patients with Esophageal Squamous Cell Carcinoma , 2015, Digestive Diseases and Sciences.
[3] R. Feng,et al. The Expression of CD30 Based on Immunohistochemistry Predicts Inferior Outcome in Patients with Diffuse Large B-Cell Lymphoma , 2015, PloS one.
[4] Jin-Ching Lin,et al. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.
[5] M. Glennie,et al. Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study , 2015, Clinical Cancer Research.
[6] Christian Adam,et al. CD40‐independent natural killer‐cell help promotes dendritic cell vaccine‐induced T‐cell immunity against endogenous B‐cell lymphoma , 2014, International journal of cancer.
[7] H. Qin,et al. Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma , 2014, Medical Oncology.
[8] Y. Wang,et al. BTG1 underexpression is an independent prognostic marker in esophageal squamous cell carcinoma , 2014, Tumor Biology.
[9] Bruce D Cheson,et al. A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors , 2014, Journal of Hematology & Oncology.
[10] Hui Li,et al. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection. , 2014, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[11] Yu-qin Pan,et al. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large B cell lymphoma patients , 2014, Annals of Hematology.
[12] A. Shenoy,et al. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients. , 2014, Oral oncology.
[13] A. Pedersen,et al. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials , 2014, Immunopharmacology and immunotoxicology.
[14] Liang Zhao,et al. The Cell Surface GRP78 Facilitates the Invasion of Hepatocellular Carcinoma Cells , 2013, BioMed research international.
[15] K. Goodman,et al. External beam radiation therapy for locally advanced and metastatic gastrointestinal stromal tumors , 2013, Radiation oncology.
[16] P. Jänne,et al. The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.
[17] Xia He,et al. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: preliminary results. , 2013, Future oncology.
[18] J. Singer,et al. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] S. Altuwaijri,et al. Intensity modulated radiotherapy of upper abdominal malignancies: dosimetric comparison with 3D conformal radiotherapy and acute toxicity , 2013, Radiation oncology.
[20] R. Langer,et al. A specific expression profile of heat-shock proteins and glucose-regulated proteins is associated with response to neoadjuvant chemotherapy in oesophageal adenocarcinomas , 2013, British Journal of Cancer.
[21] L. Vidal,et al. Anthracycline-containing regimens for treatment of follicular lymphoma in adults. , 2013, The Cochrane database of systematic reviews.
[22] J. Blay,et al. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. , 2013 .
[23] C. Gisselbrecht,et al. The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use. , 2013, The oncologist.
[24] Zongwei Li,et al. Cell-surface GRP78 facilitates colorectal cancer cell migration and invasion. , 2013, The international journal of biochemistry & cell biology.
[25] Samuel Hellman,et al. Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] W. Liu,et al. Association between Regulated upon Activation, Normal T Cells Expressed and Secreted (RANTES) -28C/G Polymorphism and Susceptibility to HIV-1 Infection: A Meta-Analysis , 2013, PloS one.
[27] Chaosu Hu,et al. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma , 2013, Journal of Cancer Research and Clinical Oncology.
[28] M. Glennie,et al. Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.
[29] D. Drazin,et al. Multiple intracranial metastases from a gastric gastrointestinal stromal tumor , 2013, Journal of Clinical Neuroscience.
[30] Carlos Caldas,et al. The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.
[31] J. Singer,et al. The Novel Anthracenedione, Pixantrone, Lacks Redox Activity and Inhibits Doxorubicinol Formation in Human Myocardium: Insight to Explain the Cardiac Safety of Pixantrone in Doxorubicin-Treated Patients , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[32] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[33] Y. Miyagi,et al. [A case of small intestinal stage IV gastrointestinal stromal tumor in which long-term disease control was maintained for more than 10 Years through a multidisciplinary team approach]. , 2012, Gan to kagaku ryoho. Cancer & chemotherapy.
[34] B. Coiffier,et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. , 2012, The Lancet. Oncology.
[35] Huahsi Wu,et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study. , 2012, European journal of cancer.
[36] P. Wei,et al. Silencing of Glucose-Regulated Protein 78 (GRP78) Enhances Cell Migration Through the Upregulation of Vimentin in Hepatocellular Carcinoma Cells , 2012, Annals of Surgical Oncology.
[37] P. Casali,et al. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST) , 2012, Current Treatment Options in Oncology.
[38] David Goldstein,et al. Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure , 2012, Clinical Cancer Research.
[39] A. King,et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] S. Sanguanrungsirikul,et al. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. , 2012, Gynecologic oncology.
[41] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[42] G. Dranoff,et al. Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.
[43] J. Eickhoff,et al. Survival of gastrointestinal stromal tumor patients in the imatinib era: life raft group observational registry , 2012, BMC Cancer.
[44] P. Edén,et al. Gene expression profiling indicates that immunohistochemical expression of CD40 is a marker of an inflammatory reaction in the tumor stroma of diffuse large B-cell lymphoma , 2012, Leukemia & lymphoma.
[45] S. Lim,et al. FAK promotes recruitment of talin to nascent adhesions to control cell motility , 2012, The Journal of cell biology.
[46] D. Dornan,et al. To respond or not to respond to CD40 agonism: That is the prediction , 2012, Oncoimmunology.
[47] X. Hao,et al. Novel immunohistochemical monoclonal antibody against human glucose-regulated protein 78. , 2011, Hybridoma.
[48] M. Koç,et al. Gastrointestinal stromal tumor of the rectum with bone and liver metastasis: a case study , 2011, Medical oncology.
[49] M. Heinrich,et al. Gastrointestinal stromal tumours: origin and molecular oncology , 2011, Nature Reviews Cancer.
[50] J. Fléjou. Classification OMS 2010 des tumeurs digestives : la quatrième édition☆ , 2011 .
[51] L. Brady,et al. Radiotherapy in the treatment of gastrointestinal stromal tumor , 2011, Rare tumors.
[52] E. Barbieri,et al. Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor , 2011, Rare tumors.
[53] M. Takemura,et al. Serum interleukin‐18 level is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with CHOP or R‐CHOP regimens , 2011, European journal of haematology.
[54] S. Groshen,et al. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. , 2011, Cancer research.
[55] A. Bazzocchi,et al. Three cases of bone metastases in patients with gastrointestinal stromal tumors , 2011, Rare tumors.
[56] J. Singer,et al. Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma , 2011, Leukemia & lymphoma.
[57] A. Lee,et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. , 2011, International journal of radiation oncology, biology, physics.
[58] Lei Yao,et al. CCL3L1 Copy Number Variation and Susceptibility to HIV-1 Infection: A Meta-Analysis , 2010, PloS one.
[59] G. Tulunay,et al. Multivariate analysis of prognostic factors in patients with stage IB cervical cancer who underwent radical hysterectomy , 2010 .
[60] Michael Hummel,et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.
[61] Huan-zhang Zhu,et al. Association between the CCR2-Val64Ile polymorphism and susceptibility to HIV-1 infection: a meta-analysis. , 2010, Molecular medicine reports.
[62] J. Blay,et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. , 2010, The Lancet. Oncology.
[63] N. Schmitz,et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] P. Bendahl,et al. CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2010, Leukemia & lymphoma.
[65] C. Du,et al. Molecular mechanisms of secondary imatinib resistance in patients with gastrointestinal stromal tumors , 2010, Journal of Cancer Research and Clinical Oncology.
[66] D. Kim,et al. Outcomes after radical hysterectomy in patients with early-stage adenocarcinoma of uterine cervix , 2010, British Journal of Cancer.
[67] D. Ennishi,et al. Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] Robin L. Jones,et al. Radiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcoma. , 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[69] Eugene H. Blackstone,et al. 7th Edition of the AJCC Cancer Staging Manual: Esophagus and Esophagogastric Junction , 2010, Annals of Surgical Oncology.
[70] M. Frómeta,et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck , 2010, Cancer biology & therapy.
[71] Young Tae Kim,et al. Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy. , 2010, Journal of gynecologic oncology.
[72] R. Gascoyne,et al. Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP , 2010, Haematologica.
[73] H. Kim,et al. Treatment outcomes and prognostic factors in uterine cervical cancer patients treated with postoperative extended field radiation therapy. , 2009, Journal of gynecologic oncology.
[74] N. Mehra,et al. Genetic determinants of HIV-1 infection and progression to AIDS: immune response genes. , 2009, Tissue antigens.
[75] C. Antonescu,et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. , 2009, The Lancet. Oncology.
[76] Narasimhan P. Agaram,et al. Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance , 2009, Clinical Cancer Research.
[77] Nancy Whiting,et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] B. Giardina,et al. New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.
[79] S. Pecorelli. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .
[80] T. Kasamatsu,et al. Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix , 2009, British Journal of Cancer.
[81] C. Greco,et al. Molecularly targeted therapy and radiotherapy in the management of localized gastrointestinal stromal tumor (GIST) of the rectum: a case report. , 2009, Tumori.
[82] M. S. Ramakrishnan,et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin , 2009, mAbs.
[83] Hao Sun,et al. Distribution of CCR5-Delta32, CCR2-64I, SDF1-3'A, CX3CR1-249I, and CX3CR1-280M in Chinese populations. , 2008, AIDS research and human retroviruses.
[84] S. Hee,et al. Treatment of nasopharyngeal carcinoma using intensity-modulated radiotherapy-the national cancer centre singapore experience. , 2008, International journal of radiation oncology, biology, physics.
[85] Wiley Interscience,et al. Association of RANTES −403 G/A, −28 C/G and In1.1 T/C polymorphism with HIV‐1 transmission and progression among North Indians , 2008, Journal of medical virology.
[86] Hua-Chuan Zheng,et al. Overexpression of GRP78 and GRP94 are markers for aggressive behavior and poor prognosis in gastric carcinomas. , 2008, Human pathology.
[87] D. Gaffney,et al. Incidence, Mortality, and Prognostic Factors of Small Cell Carcinoma of the Cervix , 2008, Obstetrics and gynecology.
[88] S. S. Kim,et al. The effects of RANTES/CCR5 promoter polymorphisms on HIV disease progression in HIV‐infected Koreans , 2008, International journal of immunogenetics.
[89] R. Langer,et al. Expression and clinical significance of Glucose Regulated Proteins GRP78 (BiP) and GRP94 (GP96) in human adenocarcinomas of the esophagus , 2008, BMC Cancer.
[90] C-C Huang,et al. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy. , 2008, European journal of cancer care.
[91] J. Nam,et al. Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[92] J. Fregnani,et al. Comparison of biological behavior between early-stage adenocarcinoma and squamous cell carcinoma of the uterine cervix. , 2008, European journal of obstetrics, gynecology, and reproductive biology.
[93] J. Crowley,et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] S. Groshen,et al. Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. , 2008, Cancer research.
[95] D. Moore,et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group , 2008, Leukemia & lymphoma.
[96] Thomas C. Chen,et al. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. , 2007, Cancer research.
[97] A. D. Van den Abbeele,et al. Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors , 2007, Clinical Cancer Research.
[98] M. Akmansu,et al. Metastatic gastrointestinal stromal tumor with long-term response after treatment with concomitant radiotherapy and imatinib mesylate. , 2007, Anti-cancer drugs.
[99] P. Venugopal,et al. Efficacy and safety of rituximab combined with ESHAP chemotherapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. , 2007, Clinical lymphoma & myeloma.
[100] Y. Xiong,et al. Prognostic factors for patients with FIGO Stage-IB cervical squamous cell carcinoma: Does the tumor size (≤ 4 cm or > 4 cm) really matter? , 2007 .
[101] J. Blay,et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[102] R. Gascoyne,et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. , 2007, Blood.
[103] Q. Zhan,et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma , 2007, Journal of Molecular Medicine.
[104] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[105] A. Tulpule,et al. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma , 2007, Leukemia & lymphoma.
[106] P. Bendahl,et al. CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma , 2007, Leukemia & lymphoma.
[107] K. Charoenkwan,et al. Clinical outcomes and prognostic factors of node-negative cervical cancer patients with deep stromal invasion or lymphovascular space involvement following radical hysterectomy. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.
[108] Farin Kamangar,et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[109] A. López-Guillermo,et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.
[110] H. Joensuu,et al. Gastrointestinal stromal tumor (GIST) , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[111] I. Lossos,et al. Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[113] J. Sham,et al. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. , 2006, International journal of radiation oncology, biology, physics.
[114] M. Lai,et al. Overexpression of glucose-regulated protein 78 in colon cancer. , 2006, Clinica chimica acta; international journal of clinical chemistry.
[115] T. Bihani,et al. Enhanced selenium effect on growth arrest by BiP/GRP78 knockdown in p53-null human prostate cancer cells , 2006, Oncogene.
[116] C. Gutiérrez,et al. Polymorphism of RANTES Chemokine Gene Promoter Is Not Associated With Long-Term Nonprogressive HIV-1 Infection of More Than 16 Years , 2006, Journal of acquired immune deficiency syndromes.
[117] G. Ahlenstiel,et al. Distribution and effects of polymorphic RANTES gene alleles in HIV/HCV coinfection -- a prospective cross-sectional study. , 2005, World journal of gastroenterology.
[118] G. Antoch,et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib , 2005, International journal of cancer.
[119] B. O'Sullivan,et al. Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[120] D. Machin,et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] K. Ohtomo,et al. Treatment results and prognostic analysis of radical radiotherapy for locally advanced cancer of the uterine cervix. , 2005, The British journal of radiology.
[122] M. van Glabbeke,et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[123] J. Blay,et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. , 2005, European journal of cancer.
[124] R. Gascoyne,et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] C. Antonescu,et al. Acquired Resistance to Imatinib in Gastrointestinal Stromal Tumor Occurs Through Secondary Gene Mutation , 2005, Clinical Cancer Research.
[126] S. Leung,et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience. , 2004, International journal of radiation oncology, biology, physics.
[127] Rossella Bertulli,et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial , 2004, The Lancet.
[128] S Ma,et al. Effects of single nucleotide polymorphisms in the RANTES promoter region in healthy and HIV-infected indigenous Chinese. , 2004, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[129] A. D. Van den Abbeele,et al. Safety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[130] N. Siddiqui,et al. Depth of cervical stromal invasion as a prognostic factor after radical surgery for early stage cervical cancer. , 2004, Gynecologic oncology.
[131] J. Koropatnick,et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] J. Sham,et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[133] Shih-hung Huang,et al. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. , 2004, Gynecologic oncology.
[134] M. Kohler,et al. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? , 2004, Gynecologic oncology.
[135] B. Goh,et al. Epidermal Growth Factor Receptor in Undifferentiated Carcinoma of the Nasopharynx , 2004, The Laryngoscope.
[136] K. Ang,et al. CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC,RTOG consensus guidelines. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[137] T. Poon,et al. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—a prospective study , 2003, Head & neck.
[138] K. Swenerton,et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[139] B. Becker,et al. How meta-analysis increases statistical power. , 2003, Psychological methods.
[140] S. Borrego,et al. Fluorescence resonance energy transfer analysis of the RANTES polymorphisms -403G --> A and -28G --> C: evaluation of both variants as susceptibility factors to HIV type 1 infection in the Spanish population. , 2003, AIDS research and human retroviruses.
[141] L. Clegg,et al. Endocrine tumors of the uterine cervix: incidence, demographics, and survival with comparison to squamous cell carcinoma. , 2003, Gynecologic oncology.
[142] Chen-Yi Hsu,et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[143] E. Deconinck,et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[144] M. Bamshad,et al. Signatures of natural selection in the human genome , 2003, Nature Reviews Genetics.
[145] S. Kvaløy,et al. Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[146] C. Fisher,et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. , 2003, Radiology.
[147] Samuel Singer,et al. PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors , 2003, Science.
[148] N. Sakuragi,et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy , 2002, Acta obstetricia et gynecologica Scandinavica.
[149] A. D. Van den Abbeele,et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.
[150] John P A Ioannidis,et al. Commentary: meta-analysis of individual participants' data in genetic epidemiology. , 2002, American journal of epidemiology.
[151] I. Fidler,et al. Critical determinants of metastasis. , 2002, Seminars in cancer biology.
[152] Roy S Herbst,et al. Monoclonal antibodies to target epidermal growth factor receptor–positive tumors , 2002, Cancer.
[153] H. Moch,et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. , 2001, The American journal of pathology.
[154] P. Xia,et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. , 2001, International journal of radiation oncology, biology, physics.
[155] O. Kallioniemi,et al. Tissue microarrays (TMAs) for high‐throughput molecular pathology research , 2001, International journal of cancer.
[156] Amy S. Lee,et al. The glucose-regulated proteins: stress induction and clinical applications. , 2001, Trends in biochemical sciences.
[157] G. Minotti,et al. Human Heart Cytosolic Reductases and Anthracycline Cardiotoxicity , 2001, IUBMB life.
[158] V. Diehl,et al. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[159] M. Hammer,et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1α: Impact on the epidemiology of the HIV-1 pandemic , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[160] D. Tuveson,et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. , 2001, The New England journal of medicine.
[161] C. Crum,et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix. , 2001, Gynecologic oncology.
[162] B. Yeap,et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. , 2001, Archives of surgery.
[163] J. Denobile,et al. CASE REPORT: Adjuvant Radiotherapy for Gastrointestinal Stromal Tumor of the Rectum , 2001, Digestive Diseases and Sciences.
[164] B. Rollins,et al. Chemokines and disease , 2001, Nature Immunology.
[165] J. Smyth,et al. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. , 2000, European journal of cancer.
[166] R. Detels,et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study , 2000, AIDS.
[167] D. Rimm,et al. Validation of Tissue Microarray Technology in Breast Carcinoma , 2000, Laboratory Investigation.
[168] S. O’Brien,et al. Influence of CCR5 promoter haplotypes on AIDS progression in African–Americans , 2000, AIDS.
[169] R. V. Vander Heide,et al. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. , 2000, Molecular genetics and metabolism.
[170] M. Runge,et al. Doxorubicin-Induced Cardiomyopathy , 2000 .
[171] Kenichi Tanaka,et al. High-risk group in node-positive patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation. , 2000, Gynecologic oncology.
[172] U. Wahn,et al. Atopic Dermatitis Is Associated with a Functional Mutation in the Promoter of the C-C Chemokine RANTES1 , 2000, The Journal of Immunology.
[173] J. Banchereau,et al. CD40‐CD40 ligand , 2000, Journal of leukocyte biology.
[174] P. Debré,et al. Distribution of HIV-1 disease modifying regulated on activation normal T cell expressed and secreted haplotypes in Asian, African and Caucasian individuals. French ALT and IMMUNOCO Study Group. , 1999, AIDS.
[175] A. Zelenetz,et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[176] P C Levendag,et al. A three-dimensional CT-based target definition for elective irradiation of the neck. , 1999, International journal of radiation oncology, biology, physics.
[177] B. Monk,et al. Young age as a prognostic factor in cervical cancer: results of a population-based study. , 1999, American journal of obstetrics and gynecology.
[178] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[179] K Fukutake,et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[180] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[181] D. Baltimore,et al. Specificities of CD40 signaling: involvement of TRAF2 in CD40-induced NF-kappaB activation and intercellular adhesion molecule-1 up-regulation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[182] J. Goedert,et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. , 1998, Science.
[183] J. Blay,et al. Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. , 1998, Blood.
[184] L. Kindblom,et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. , 1998, The American journal of pathology.
[185] M. Mack,et al. Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.
[186] J. Cooper,et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[187] L. Roman,et al. Influence of quantity of lymph-vascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix. , 1998, Gynecologic oncology.
[188] A. Luster,et al. Chemokines--chemotactic cytokines that mediate inflammation. , 1998, The New England journal of medicine.
[189] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[190] J J Goedert,et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) , 1998, Science.
[191] P. Lipsky,et al. Bidirectional regulation of human B cell responses by CD40-CD40 ligand interactions. , 1997, Journal of immunology.
[192] S. Sheen-Chen,et al. Smooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. , 1996, Surgery.
[193] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[194] G. Pezzoni,et al. Anthracene-9,10-Diones and Aza Bioisosteres as Antitumor Agents , 1995, Current Medicinal Chemistry.
[195] J. Chmiel,et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? , 1995, Cancer.
[196] M. Hacker,et al. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. , 1995, Biochemical pharmacology.
[197] G. Capranico,et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. , 1995, Molecular pharmacology.
[198] M. Hacker,et al. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. , 1995, Cancer letters.
[199] S. Tucker,et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[200] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[201] L. Zwelling,et al. Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. , 1993, Biochemical pharmacology.
[202] C. Fletcher,et al. Gastrointestinal stromal tumours: Correlation of immunophenotype with clinicopathological features , 1991, The Journal of pathology.
[203] P. Smith,et al. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells. , 1990, Biochemical pharmacology.
[204] M. Dong,et al. GRP78 promotes the invasion of pancreatic cancer cells by FAK and JNK , 2014, Molecular and Cellular Biochemistry.
[205] M. Søgaard,et al. Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma. , 2013, Asian Pacific journal of cancer prevention : APJCP.
[206] J. Luketich,et al. Oesophageal carcinoma , 2013, The Lancet.
[207] R. Shui,et al. Prognostic factors and treatment comparison in early-stage small cell carcinoma of the uterine cervix. , 2012, Oncology letters.
[208] Jordi Giralt,et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.
[209] M. Yan,et al. Influence of lymph vascular space invasion on prognosis of patients with early-stage cervical squamous cell carcinoma. , 2010, Chinese journal of cancer.
[210] Ji-Hong Liu,et al. Risk factors and prognosis of IB-IIB cervical carcinoma with common iliac lymph node metastasis. , 2010, Chinese journal of cancer.
[211] Huijuan Song,et al. Grp78 promotes the invasion of hepatocellular carcinoma. , 2010, BMC cancer.
[212] B. Hallberg,et al. c-Kit--a hematopoietic cell essential receptor tyrosine kinase. , 2007, The international journal of biochemistry & cell biology.
[213] L. Dawson,et al. Upper abdominal malignancies: intensity-modulated radiation therapy. , 2007, Frontiers of radiation therapy and oncology.
[214] M. Zelefsky,et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. , 2006, International journal of radiation oncology, biology, physics.
[215] S. O’Brien,et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. , 2006, The Journal of infectious diseases.
[216] R. K. Sachdeva,et al. Gene Polymorphisms in CCR5, CCR2, CX3CR1, SDF-1 and RANTES in Exposed but Uninfected Partners of HIV-1 Infected Individuals in North India , 2006, Journal of Clinical Immunology.
[217] E. Glatstein. Gastrointestinal Stromal Tumor: New Nodule-Within-a-Mass Pattern of Recurrence After Partial Response to Imatinib Mesylate , 2006 .
[218] W. Hop,et al. Prognostic factors in adenocarcinoma of the uterine cervix. , 2004, Gynecologic oncology.
[219] C. Gisselbrecht,et al. Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. , 2003, Haematologica.
[220] R. Wenham,et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. , 2002, Gynecologic oncology.
[221] E. Raymond,et al. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[222] A. Davis,et al. Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective Database , 2001 .
[223] J. Lasota,et al. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis , 2000, Virchows Archiv.
[224] R. DeMatteo,et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. , 2000, Annals of surgery.
[225] J. Farber,et al. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.
[226] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[227] J. Gribben,et al. Unbalanced expression of bcl-2 family proteins in follicular lymphoma: contribution of CD40 signaling in promoting survival. , 1998, Blood.
[228] L. Sobin,et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. , 1997, Archives of pathology & laboratory medicine.
[229] Amy S. Lee,et al. The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. , 1994, Critical reviews in eukaryotic gene expression.
[230] A. Bird. Immunology of HIV Infection , 1992, Immunology and Medicine Series.
[231] S. Jagannath,et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). , 1988, Blood.
[232] M. Serdar,et al. Oncotargets and Therapy , 2022 .